| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2006-10-16 12:25:20 UTC |
|---|
| Update Date | 2022-03-07 02:49:25 UTC |
|---|
| HMDB ID | HMDB0005006 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Atorvastatin |
|---|
| Description | Atorvastatin is a member of the drug class known as statins, used for lowering cholesterol and thereby reducing cardiovascular disease. Atorvastatin inhibits a rate-determining enzyme located in hepatic tissue used in cholesterol synthesis, which lowers the amount of cholesterol produced. This also has the effect of lowering the total amount of LDL cholesterol; Atorvastatin is a member of the drug class known as statins, used for lowering cholesterol and thereby reducing cardiovascular disease. Atorvastatin inhibits a rate-determining enzyme located in hepatic tissue used in cholesterol synthesis, which lowers the amount of cholesterol produced. This also has the effect of lowering the total amount of LDL cholesterol; As with other statins, atorvastatin is a competitive inhibitor of HMG-CoA reductase. Unlike most others, however, it is a completely synthetic compound. HMG-CoA reductase catalyzes the reduction of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, which is the rate-limiting step in hepatic cholesterol biosynthesis. Inhibition of the enzyme decreases de novo cholesterol synthesis, increasing expression of low-density lipoprotein receptors (LDL receptors) on hepatocytes. This increases the LDL uptake by the hepatocytes, decreasing the amount of LDL in the blood. |
|---|
| Structure | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1 InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid | ChEBI | | 7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID | ChEBI | | Atorlip | ChEBI | | Atorpic | ChEBI | | Atorvastatina | ChEBI | | Atorvastatine | ChEBI | | Atorvastatinum | ChEBI | | Liprimar | ChEBI | | Lipitor | Kegg | | Sortis | Kegg | | (R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate | Generator | | (R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid | Generator | | (R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate | Generator | | (R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate | Generator | | (R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid | Generator | | 7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate | Generator | | Atorvastatin calcium hydrate | MeSH | | (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid | MeSH | | Atorvastatin calcium | MeSH | | Atorvastatin calcium trihydrate | MeSH | | Atorvastatin, calcium salt | MeSH | | Liptonorm | MeSH | | Atorvastatin calcium anhydrous | MeSH | | (R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate | Generator, HMDB | | (R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid | Generator, HMDB | | Atorvastatin acid | HMDB | | Cardyl | HMDB | | Anhydrous, atorvastatin calcium | MeSH, HMDB | | Calcium hydrate, atorvastatin | MeSH, HMDB | | Calcium trihydrate, atorvastatin | MeSH, HMDB | | Calcium, atorvastatin | MeSH, HMDB | | Hydrate, atorvastatin calcium | MeSH, HMDB | | Trihydrate, atorvastatin calcium | MeSH, HMDB | | Calcium anhydrous, atorvastatin | MeSH, HMDB | | Calcium salt atorvastatin | MeSH, HMDB |
|
|---|
| Chemical Formula | C33H35FN2O5 |
|---|
| Average Molecular Weight | 558.6398 |
|---|
| Monoisotopic Molecular Weight | 558.253000445 |
|---|
| IUPAC Name | (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid |
|---|
| Traditional Name | atorvastatin |
|---|
| CAS Registry Number | 134523-00-5 |
|---|
| SMILES | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 |
|---|
| InChI Key | XUKUURHRXDUEBC-KAYWLYCHSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as diphenylpyrroles. These are aromatic heterocyclic compounds with a structure based on a pyrrole ring linked to exactly two phenyl groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Pyrroles |
|---|
| Sub Class | Substituted pyrroles |
|---|
| Direct Parent | Diphenylpyrroles |
|---|
| Alternative Parents | |
|---|
| Substituents | - 2,3-diphenylpyrrole
- Aromatic anilide
- Medium-chain hydroxy acid
- Pyrrole-3-carboxamide
- Pyrrole-3-carboxylic acid or derivatives
- Medium-chain fatty acid
- Beta-hydroxy acid
- Fluorobenzene
- Halobenzene
- Halogenated fatty acid
- Heterocyclic fatty acid
- Hydroxy fatty acid
- Aryl fluoride
- Aryl halide
- Monocyclic benzene moiety
- Hydroxy acid
- Fatty acyl
- Fatty acid
- Benzenoid
- Vinylogous amide
- Heteroaromatic compound
- Secondary carboxylic acid amide
- Secondary alcohol
- Carboxamide group
- Monocarboxylic acid or derivatives
- Azacycle
- Carboxylic acid derivative
- Carboxylic acid
- Carbonyl group
- Organopnictogen compound
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organonitrogen compound
- Organooxygen compound
- Organic nitrogen compound
- Alcohol
- Organohalogen compound
- Organofluoride
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 159.1 - 190.6 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 8.07 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 15.7682 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.72 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 55.5 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3256.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 229.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 243.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 180.1 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 203.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 727.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 631.1 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 84.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1380.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 652.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1784.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 433.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 459.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 165.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 73.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Atorvastatin,1TMS,isomer #1 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C | 4320.6 | Semi standard non polar | 33892256 | | Atorvastatin,1TMS,isomer #2 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C | 4322.9 | Semi standard non polar | 33892256 | | Atorvastatin,1TMS,isomer #3 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C | 4271.6 | Semi standard non polar | 33892256 | | Atorvastatin,1TMS,isomer #4 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O | 4158.4 | Semi standard non polar | 33892256 | | Atorvastatin,2TMS,isomer #1 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O)O[Si](C)(C)C)O[Si](C)(C)C | 4305.7 | Semi standard non polar | 33892256 | | Atorvastatin,2TMS,isomer #2 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 4265.5 | Semi standard non polar | 33892256 | | Atorvastatin,2TMS,isomer #3 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C | 4138.0 | Semi standard non polar | 33892256 | | Atorvastatin,2TMS,isomer #4 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 4269.1 | Semi standard non polar | 33892256 | | Atorvastatin,2TMS,isomer #5 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C | 4157.7 | Semi standard non polar | 33892256 | | Atorvastatin,2TMS,isomer #6 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C | 4113.0 | Semi standard non polar | 33892256 | | Atorvastatin,3TMS,isomer #1 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 4278.8 | Semi standard non polar | 33892256 | | Atorvastatin,3TMS,isomer #2 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O)O[Si](C)(C)C)O[Si](C)(C)C | 4158.7 | Semi standard non polar | 33892256 | | Atorvastatin,3TMS,isomer #3 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 4118.1 | Semi standard non polar | 33892256 | | Atorvastatin,3TMS,isomer #4 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 4127.9 | Semi standard non polar | 33892256 | | Atorvastatin,4TMS,isomer #1 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 4143.2 | Semi standard non polar | 33892256 | | Atorvastatin,4TMS,isomer #1 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 3386.1 | Standard non polar | 33892256 | | Atorvastatin,4TMS,isomer #1 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 4792.1 | Standard polar | 33892256 | | Atorvastatin,1TBDMS,isomer #1 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C(C)(C)C | 4509.1 | Semi standard non polar | 33892256 | | Atorvastatin,1TBDMS,isomer #2 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C | 4501.3 | Semi standard non polar | 33892256 | | Atorvastatin,1TBDMS,isomer #3 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C(C)(C)C | 4487.3 | Semi standard non polar | 33892256 | | Atorvastatin,1TBDMS,isomer #4 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C(C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O | 4359.5 | Semi standard non polar | 33892256 | | Atorvastatin,2TBDMS,isomer #1 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4647.0 | Semi standard non polar | 33892256 | | Atorvastatin,2TBDMS,isomer #2 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4632.1 | Semi standard non polar | 33892256 | | Atorvastatin,2TBDMS,isomer #3 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C(C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C(C)(C)C | 4494.1 | Semi standard non polar | 33892256 | | Atorvastatin,2TBDMS,isomer #4 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4622.1 | Semi standard non polar | 33892256 | | Atorvastatin,2TBDMS,isomer #5 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C(C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C | 4511.9 | Semi standard non polar | 33892256 | | Atorvastatin,2TBDMS,isomer #6 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C(C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C(C)(C)C | 4481.4 | Semi standard non polar | 33892256 |
|
|---|
| Spectra |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (Non-derivatized) - 70eV, Positive | splash10-000f-5100950000-b76d194b9679e4b35417 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (1 TMS) - 70eV, Positive | splash10-082i-5320938000-c1984e6bf123460d28ac | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS ("Atorvastatin,1TMS,#1" TMS) - 70eV, Positive | Not Available | 2021-10-14 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_3_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_3_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_3_4) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_1_4) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_2_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_2_4) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_2_5) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-QTOF , negative-QTOF | splash10-0a4i-0000090000-ae5c999b091a2bc93933 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-QTOF , negative-QTOF | splash10-0a4i-0000190000-dd563e18b1f0f74aadd5 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-QTOF , negative-QTOF | splash10-0zfs-0007960000-cb66a18d2f0a687261ba | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-QTOF , negative-QTOF | splash10-002b-0059000000-0942bc1e35434cd7d0d3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-QTOF , negative-QTOF | splash10-004i-0093000000-f42ba46820a3cf3295c5 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0udj-0005910000-b09ba5f3b86948c7f3cb | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0000090000-6f297ca79ae1761aac33 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0002-1009300000-9479520f395dcdd585e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-004i-0092000000-9b561b8d35c3bdc5e46a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-004i-0090000000-3aad87273e7f9942a50f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-01t9-1090000000-3f0efff41ebdb5320ce4 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-03di-2090000000-0227638704b90c4249d0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0000090000-65c729c6734f6533c431 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0002-1009300000-9122e4479d8c0c32bb0d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-004i-0092000000-22d639a8882509e1bcdb | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-004i-0090000000-30a0198165bae85fa258 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-01t9-1090000000-cb3feea45f5280f05c37 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-03di-2090000000-8db2f70b373277f143c0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0udj-0005910000-a63c845ca248d958068d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 10V, Positive-QTOF | splash10-006x-1000190000-5418613834968283e5a8 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 20V, Positive-QTOF | splash10-006y-3101940000-2906ea9feb05e2fc0cfc | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 40V, Positive-QTOF | splash10-006x-8438900000-f5abfdde8ad50c98b16e | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 10V, Negative-QTOF | splash10-0a4i-1000290000-949ba837ddf712ee8558 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 20V, Negative-QTOF | splash10-0a4s-6203960000-9adcd151fdfe389c7d00 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 40V, Negative-QTOF | splash10-054o-9158000000-7b64ce4c34d6e9fae2b8 | 2017-07-26 | Wishart Lab | View Spectrum |
|
|---|
| Biological Properties |
|---|
| Cellular Locations | - Membrane (predicted from logP)
|
|---|
| Biospecimen Locations | |
|---|
| Tissue Locations | |
|---|
| Pathways | |
|---|
| Normal Concentrations |
|---|
| |
| Blood | Detected and Quantified | 0.010 +/- 0.0044 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details |
|
|---|
| Abnormal Concentrations |
|---|
| |
| Blood | Detected and Quantified | 0.22 +/- 0.16 uM | Adult (>18 years old) | Both | Sepsis | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal Cancer | | details |
|
|---|
| Associated Disorders and Diseases |
|---|
| Disease References | | Sepsis |
|---|
- Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones M: A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med. 2009 Apr;35(4):717-21. doi: 10.1007/s00134-008-1358-3. Epub 2008 Nov 26. [PubMed:19034423 ]
| | Colorectal cancer |
|---|
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
|
|
|---|
| Associated OMIM IDs | |
|---|
| External Links |
|---|
| DrugBank ID | DB01076 |
|---|
| Phenol Explorer Compound ID | Not Available |
|---|
| FooDB ID | FDB023579 |
|---|
| KNApSAcK ID | Not Available |
|---|
| Chemspider ID | 54810 |
|---|
| KEGG Compound ID | C06834 |
|---|
| BioCyc ID | Not Available |
|---|
| BiGG ID | Not Available |
|---|
| Wikipedia Link | Atorvastatin |
|---|
| METLIN ID | 1136 |
|---|
| PubChem Compound | 60823 |
|---|
| PDB ID | Not Available |
|---|
| ChEBI ID | 39548 |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | Not Available |
|---|
| MarkerDB ID | MDB00000466 |
|---|
| Good Scents ID | Not Available |
|---|
| References |
|---|
| Synthesis Reference | Roth, Bruce David. Preparation of anticholesteremic (R-(R*R*))-2-(4-fluorophenyl)-b, d-dihydroxy-5-(1-methylethyl-3-phenyl-4((phenylamino)carbonyl)-1H-pyrrolyl-1-heptanoic acid, its lactone form and salts thereof. Eur. Pat. Appl. (1991), 18 pp. CODEN: EPXXDW EP 409281 A1 19910123 CAN 115:29107 AN 1991:429107 |
|---|
| Material Safety Data Sheet (MSDS) | Not Available |
|---|
| General References | - Taylor PJ, Kubler PA, Lynch SV, Allen J, Butler M, Pillans PI: Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother. 2004 Feb;38(2):205-8. Epub 2003 Dec 19. [PubMed:14742751 ]
- Funatsu T, Suzuki K, Goto M, Arai Y, Kakuta H, Tanaka H, Yasuda S, Ida M, Nishijima S, Miyata K: Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis. 2001 Jul;157(1):107-15. [PubMed:11427209 ]
- Tannous M, Cheung R, Vignini A, Mutus B: Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost. 1999 Nov;82(5):1390-4. [PubMed:10595624 ]
- Naoumova RP, Dunn S, Rallidis L, Abu-Muhana O, Neuwirth C, Rendell NB, Taylor GW, Thompson GR: Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res. 1997 Jul;38(7):1496-500. [PubMed:9254075 ]
- Izar MC: [Hypolipidemic treatment under special conditions: posttransplant and/or immunosuppressive therapy]. Arq Bras Cardiol. 2005 Oct;85 Suppl 5:50-7. Epub 2006 Jan 2. [PubMed:16400400 ]
- Hwang YS, Tsai WC, Lu YH, Lin CC, Chen YF: Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia. Am J Cardiol. 2004 Aug 1;94(3):364-6. [PubMed:15276107 ]
- Bruni F, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Sawamura T, Gioffre WR, Auteri A, Puccetti L: Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects. Clin Appl Thromb Hemost. 2005 Oct;11(4):417-28. [PubMed:16244767 ]
- Fenton JW 2nd, Brezniak DV, Ofosu FA, Shen GX, Jacobson JR, Garcia JG: Statins and thrombin. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Apr;5(2):115-20. [PubMed:15853752 ]
- Pokrovskaia EV, Vaulin NA, Gratsianskii NA, Averkov OV, Deev AD: [Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin]. Kardiologiia. 2003;43(1):7-18. [PubMed:12891281 ]
- Funatsu T, Kakuta H, Tanaka H, Arai Y, Suzuki K, Miyata K: [Atorvastatin (Lipitor): a review of its pharmacological and clinical profile]. Nihon Yakurigaku Zasshi. 2001 Jan;117(1):65-76. [PubMed:11233299 ]
- Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniades C, Katsi V, Stefanadis C: Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. Int J Cardiol. 2006 Jan 26;106(3):333-7. [PubMed:16337041 ]
- Malinowski JM: Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm. 1998 Nov 1;55(21):2253-67; quiz 2302-3. [PubMed:9825877 ]
|
|---|